London, United Kingdom:Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive licensing and commercialisation agreement with Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercialising precision, cell targeting therapies based on its proprietary Alluminox™ platform. Under the terms of the agreement, Hikma has an exclusive license to commercialise products in Rakuten Medical’s pipeline using its photoimmunotherapy technology platform, Alluminox™, in all its MENA markets. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe. Rakuten Medical is committed to its mission to conquer cancer by delivering our innovative treatments as quickly as possible to as many patients as possible all over the world. Rakuten Medical is developing the Alluminox™ platform as a technology consisting of a drug, device, and other related components.

Source: The North Africa Journal August 11, 2023 03:51 UTC